Thanks to Gavi’s work in the past two decades, staggering progress has been made. Child mortality is at its lowest, and today’s generation is set to be the healthiest yet. Since its inception, Gavi has protected a whole generation of children, 760 million of them, and saved over 13 million lives from potentially fatal infectious diseases.
When Gavi, the Vaccine Alliance was established in 2000, almost ten million children globally would die annually before their fifth birthday. By 2017, this number had almost halved.
IFFIm delivers value to Gavi by:
IFFIm’s frontloaded funding model helps reduce vaccine costs and shape the market. IFFIm’s support for the pentavalent vaccine provides an example of this mechanism at work. Pentavalent is a vaccine that protects from five diseases (Diphtheria, Pertussis, Tetanus, Hepatitis B and Hib). IFFIm funded more than 90% of the initial vaccine cost for Gavi’s pentavalent programme. This investment encouraged manufactures to increase production and decrease the price. Gavi is now able to procure pentavalent vaccines for $0.68 per dose, a price reduction of more than 75% since 2006.
IFFIm has played a critical role in the fight to end polio by providing funding that has helped slash incidence of the disease. When the Global Polio Eradication Initiative (GPEI) faced a crisis in 2006, it turned to IFFIm as the only way to finance stockpiling the polio vaccine so suppliers have it available for outbreaks. IFFIm invested US$191.28 million to help develop and license oral polio vaccine (OPV) products that could be field tested for safety and purchased in bulk. IFFIm’s support contributed to a striking 95% decline in polio cases in Nigeria and India, and an 85 % decline in type 3 polio cases globally.
IFFIm has raised US$ 6.5 billion in the global capital markets to fund Gavi programmes. Learn how IFFIm funds have created a financial lifeline stretching from savvy and socially responsible investors to the world’s poorest communities.
IFFIm and Gavi are continuing the fight against vaccine-preventable diseases in Nigeria, where polio is still endemic.
IFFIm supports low-income countries applying for Gavi's new and underused vaccine support.
Routine immunisation programmes supported by Gavi, with IFFIm funding, have an impact that’s anything but ordinary.
Tens of millions of mothers have been been vaccinated with tetanus toxoid thanks to IFFIm support for the MNT Elimination initiative.
IFFIm's investment in the Measles Initiative has played a key part in achieving the goal of reducing measles deaths by 90%.
As of December 2017, IFFIm has disbursed US$ 277 million for Gavi's health system strengthening (HSS) support.
IFFIm has provided Gavi with more than US$ 1 billion toward the purchase of pentavalent vaccine.
Gavi's participation in the campaign against meningitis in Africa has received more than US$ 60 million from IFFIm